Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matria Healthcare (MATR) -- Ignore unavailable to you. Want to Upgrade?

To: Thomas W. O'Brien who wrote (101)	1/13/1998 9:33:00 AM
From: GREATMOOD	Respond to of 220

Thomas, Good to hear from you. The market for Matria stock has gotten very thin with lots of investors staying on the sidelines until the general market malaise eases. It's fallen on light volume, and the selling has basically been small lots. The recent run-up was not only based on the Dr. Jay Iams editorial, but there was a story going around that Johnson and Johnson may be interested in buying Matria! The terbutalene issue that the FDA spoke about last month has probably played a factor in some of the recent "retail" selling, but on a positive note, the approval of Johnson and Johnson's far safer ANTOCIN is on track for February. (Under the new FDA guidelines, they must respond on the ANTOCIN application by February 1998). On a new front, Matria's management said that they are very "excited" about a new revenue source they introduced in June 1997: AN AUTOMATED CLINICAL RECORD SYSTEM FOR OB/GYN This is a high margin business with a potential of $50 - $60 million. They have a salesforce of about 10 people, and the acceptance so far has been excellent! BTW this new product competes against some Wall Steet "darlings" that command premium multiples! GM